pubmed-article:17072336 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17072336 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
pubmed-article:17072336 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
pubmed-article:17072336 | lifeskim:mentions | umls-concept:C0021760 | lld:lifeskim |
pubmed-article:17072336 | lifeskim:mentions | umls-concept:C0178539 | lld:lifeskim |
pubmed-article:17072336 | lifeskim:mentions | umls-concept:C0596138 | lld:lifeskim |
pubmed-article:17072336 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
pubmed-article:17072336 | lifeskim:mentions | umls-concept:C1366587 | lld:lifeskim |
pubmed-article:17072336 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
pubmed-article:17072336 | lifeskim:mentions | umls-concept:C0127400 | lld:lifeskim |
pubmed-article:17072336 | pubmed:issue | 20 | lld:pubmed |
pubmed-article:17072336 | pubmed:dateCreated | 2007-5-3 | lld:pubmed |
pubmed-article:17072336 | pubmed:abstractText | Levels of the proinflammatory cytokine interleukin-6 (IL-6) are increased in therapy-resistant prostate cancer. IL-6 has been considered a positive growth factor in late-stage prostate cancer cells and a potential target for therapeutic interference. Effects of inhibition of IL-6 on cell survival were studied in LNCaP-IL6+ cells, a model system for advanced prostate cancer, which produce IL-6. We show that the autocrine IL-6 loop is responsible for resistance to apoptosis and increased cellular levels of myeloid cell leukemia-1 (Mcl-1) protein, an antiapoptotic member of the Bcl-2 family. Treatment of cells with a chimeric anti-IL-6 antibody (CNTO 328) led to the induction of apoptosis and downregulation of Mcl-1 protein levels. Specific knockdown of Mcl-1 gene expression by small interfering RNA also yielded an increase in apoptosis of LNCaP-IL-6+ cells. Vice versa, inactivation of IL-6 autocrine loop had no influence on apoptosis levels in the absence of Mcl-1, thus suggesting this molecule as a mediator of the survival action of IL-6. Mcl-1 protein regulation by the endogenous cytokine directly involved the extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway. Our data support the concept of anti-IL-6 targeted therapy in therapy-resistant prostate cancer. | lld:pubmed |
pubmed-article:17072336 | pubmed:language | eng | lld:pubmed |
pubmed-article:17072336 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17072336 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17072336 | pubmed:month | May | lld:pubmed |
pubmed-article:17072336 | pubmed:issn | 0950-9232 | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:SteinerHH | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:FuchsDD | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:ZakiM HMH | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:RumpoldHH | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:HobischAA | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:CuligZZ | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:UntergasserGG | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:NemethJ AJA | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:MoserP LPL | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:CavarrettaI... | lld:pubmed |
pubmed-article:17072336 | pubmed:author | pubmed-author:NeuwirtHH | lld:pubmed |
pubmed-article:17072336 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:17072336 | pubmed:day | 3 | lld:pubmed |
pubmed-article:17072336 | pubmed:volume | 26 | lld:pubmed |
pubmed-article:17072336 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17072336 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17072336 | pubmed:pagination | 2822-32 | lld:pubmed |
pubmed-article:17072336 | pubmed:dateRevised | 2011-7-29 | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:meshHeading | pubmed-meshheading:17072336... | lld:pubmed |
pubmed-article:17072336 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17072336 | pubmed:articleTitle | The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. | lld:pubmed |
pubmed-article:17072336 | pubmed:affiliation | Department of Urology, Innsbruck Medical University, Innsbruck, Austria. | lld:pubmed |
pubmed-article:17072336 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17072336 | pubmed:publicationType | Comparative Study | lld:pubmed |
entrez-gene:4170 | entrezgene:pubmed | pubmed-article:17072336 | lld:entrezgene |
http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:17072336 | lld:entrezgene |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17072336 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17072336 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17072336 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17072336 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17072336 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17072336 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17072336 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17072336 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17072336 | lld:pubmed |